美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

猴痘概念

2,076.62

+17.200.84%

漲家數：2

跌家數：8

平家數：1

市盈率：- -

高：2,076.98

開：2,068.67

低：2,031.39

收：2,059.42

成交量：1,766.91萬

成交額：11.27億

市值：2,287.80億

流通市值：2,280.76億

資料載入中...

總覽新聞資訊

吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章

吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及

吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性

吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平

吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市

Leerink基於增長勢頭改善，給予Viatris「跑贏大盤」評級

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

第4次更新-鑑於市場供應存在擔憂，美國食品藥品監督管理局正與製造商合作，以增加雌激素貼片的供應量

Emergent BioSolutions圓滿完成7500萬美元優先無擔保票據回購

Emergent BioSolutions獲增購Cyfendus（Av7909）合同修訂——SEC文件披露

BUZZ——美國股市動態-Fervo Energy、Myriad Genetics、Emergent BioSolutions

Emergent因獲得2400萬美元炭疽疫苗訂單股價上漲

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK4583/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"猴痘概念","latestPrice":2076.6218,"timestamp":1789502399999,"preClose":2059.4172,"halted":0,"volume":17669108,"delay":0,"changeRate":0.008354,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":17.20459,"latestTime":"09-15 16:00:00 EDT","open":2068.673,"high":2076.981,"low":2031.3905,"amount":1127152805.473918,"amplitude":0.022138,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.52008,"peRate":-73.97734,"turnoverRate":0.006539,"increases":1,"decrements":9,"flats":0,"marketCap":228779839350.875,"floatMarketCap":228075951259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":2076.981,"amplitude":0.022138,"preClose":2059.4172,"low":2031.3905,"pbRate":"6.52008","latestPrice":2076.6218,"volume":17669108,"delay":0,"open":2068.673,"prevYearClose":1682.3505,"prevWeekClose":2024.5422,"prevMonthClose":2060.2607,"prevQuarterClose":1802.0435,"fiveDayClose":2059.5327,"twentyDayClose":1968.0898,"sixtyDayClose":1750.8007,"secType":"PLATE","market":"US","turnoverRate":0.006539,"peRate":-73.97734,"marketCap":228779839350.875,"floatMarketCap":228075951259,"timestamp":1789502399999,"nameCN":"猴痘概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":2,"down":8,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1120765496","title":"吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU0114720955.EUR","IE00BSNM7G36.USD","BK4139","BK4583","LU1023059063.AUD","LU0289739699.SGD","LU0965509283.SGD","LU1066051498.USD","LU1778281490.HKD","LU0859254822.USD","LU1430594728.SGD","MEDI","LU0320765992.SGD","LU0965509101.SGD","LU2357627491.SGD","SG9999015986.USD","IE00B19Z3581.USD","IE00B3T34201.USD","LU2089984988.USD","BBH","LU2468319806.SGD","GILD","BK4568","LU0122379950.USD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU1057294990.SGD","BK4585","BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1674673428.USD","LU1934455277.USD","LU1585245621.USD","LU0109394709.USD","BK4550","LU0058720904.USD","LU0882574055.USD","LU1934455863.HKD","TMED","LU1061106388.HKD","LU1934455194.USD","LU0965508806.USD","TBXU","LU1674673691.USD","BK4566","LU1066053197.SGD","LU1037948897.HKD","LU0234570918.USD","LU0965509010.AUD","LU0823416689.USD","LU1037948541.HKD","IBBQ","BIB","LU0889565916.HKD","LU1839511570.USD","SG9999015952.SGD","BK4532","BMED","IE00B7SZLL34.SGD","LU0861579265.USD","SG9999015978.USD","LU2087621335.USD","BK4578","IE0002270589.USD","LU2112291526.USD","LU2324357040.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","BK4550","LU0823416689.USD","IE00B3T34201.USD","LU1430594728.SGD","SG9999015945.SGD","BBH","BK4139","BK4588","LU0109394709.USD","LU0320765992.SGD","LU1571399168.USD","IBBQ","LU0965509283.SGD","LU1585245621.USD","MEDI","LU2089984988.USD","BK4578","SG9999015986.USD","LU1066051498.USD","LU1839511570.USD","BK4583","LU0122379950.USD","LU2324357040.USD","LU1674673428.USD","SG9999015978.USD","LU0859254822.USD","LU0882574055.USD","LU0965509010.AUD","LU1057294990.SGD","LU1061106388.HKD","LU2468319806.SGD","LU2112291526.USD","BK4532","LU0965509101.SGD","BMED","LU1934455194.USD","LU1037948541.HKD","LU2357627491.SGD","IBB","LU1674673691.USD","BK4585","TBXU","LU0861579265.USD","LU0234570918.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1037948897.HKD","LU1934455277.USD","BK4568","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066053197.SGD","LU2087621335.USD","LU1934455863.HKD","SG9999015952.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","BIB","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","TMED","LU0058720904.USD","IE00BSNM7G36.USD","GILD","BK4566","LU0965508806.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","LU0965509283.SGD","IE00B19Z3B42.SGD","IBB","IE00B19Z3581.USD","LU0965509101.SGD","BBH","BK4585","LU1778281490.HKD","BIB","LU1037948897.HKD","SG9999015945.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948541.HKD","LU1430594728.SGD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1674673428.USD","TBXU","LU2324357040.USD","LU1839511570.USD","LU1934455277.USD","BK4139","BK4568","LU1023059063.AUD","SG9999015986.USD","LU0234570918.USD","BK4588","IE00B3T34201.USD","BK4578","LU1934455194.USD","MEDI","LU2112291526.USD","SG9999015978.USD","SG9999015952.SGD","BMED","LU0122379950.USD","LU0109394709.USD","LU1061106388.HKD","LU1066051498.USD","LU0058720904.USD","LU0861579265.USD","LU2089984988.USD","LU0965508806.USD","TMED","LU1585245621.USD","GILD","IE0002270589.USD","LU0882574055.USD","LU0289739699.SGD","LU0114720955.EUR","BK4532","IE00B7SZLL34.SGD","BK4566","LU2087621335.USD","LU0965509010.AUD","LU1674673691.USD","LU1066053197.SGD","LU0320765992.SGD","LU0889565916.HKD","LU1934455863.HKD","LU0823416689.USD","LU1057294990.SGD","LU2468319806.SGD","LU2357627491.SGD","BK4550","LU1571399168.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","LU0058720904.USD","BK4139","BIB","LU0965509283.SGD","TBXU","LU2324357040.USD","BK4550","IE00BSNM7G36.USD","LU0114720955.EUR","LU0234570918.USD","LU0289739699.SGD","LU1571399168.USD","IE00B7SZLL34.SGD","LU1066051498.USD","LU1037948541.HKD","LU0122379950.USD","LU1430594728.SGD","SG9999015986.USD","LU1061106388.HKD","LU0965508806.USD","LU2357627491.SGD","BK4578","BK4566","IE00B19Z3B42.SGD","LU0109394709.USD","LU1585245621.USD","SG9999015978.USD","BBH","LU1674673691.USD","LU1023059063.AUD","LU1066053197.SGD","LU0889565916.HKD","LU1934455277.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4532","BK4568","LU0320765992.SGD","LU1057294990.SGD","LU0861579265.USD","LU1934455194.USD","IE00B3T34201.USD","LU0823416689.USD","IBB","LU1674673428.USD","LU1934455863.HKD","BK4588","IE00B19Z3581.USD","LU2087621335.USD","LU2112291526.USD","LU2468319806.SGD","SG9999015952.SGD","BMED","IE0002270589.USD","LU1037948897.HKD","IBBQ","LU0882574055.USD","LU0965509010.AUD","SG9999015945.SGD","TMED","BK4585","BK4583","LU1839511570.USD","MEDI","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580494","title":"Leerink基於增長勢頭改善，給予Viatris「跑贏大盤」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580494","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580494?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:48","pubTimestamp":1788954528,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink基于增长势头改善，给予Viatris“跑赢大盘”评级9月9日-** 利林克合伙公司（Leerink Partners）首次覆盖制药公司维亚特里斯（Viatris，VTRS.O），给予“跑赢大盘”评级，目标价为20美元** 该券商预计，在连续三年下滑后，2026年该公司营收和调整后EBITDA将实现增长，其预测值接近公司预期和市场预期的上限** 认为随着维亚特里斯仿制药业务趋","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4S45110L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4583","BK4588","LU1839511570.USD","BK4007","LU2087621335.USD","VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU1934455194.USD","TMED","LU2087621335.USD","LU1430594728.SGD","LU1778281490.HKD","LU0882574055.USD","LU0965509101.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948897.HKD","TBXU","IE0002270589.USD","IE00B3T34201.USD","LU0861579265.USD","LU0114720955.EUR","BK4139","IBBQ","LU0823416689.USD","LU0965509010.AUD","LU1066051498.USD","LU2089984988.USD","LU2357627491.SGD","LU0889565916.HKD","LU1674673428.USD","LU0859254822.USD","LU0289739699.SGD","LU0965508806.USD","LU1061106388.HKD","LU1674673691.USD","LU1934455277.USD","LU1839511570.USD","LU1023059063.AUD","BK4585","LU1571399168.USD","BK4578","LU1934455863.HKD","IE00BSNM7G36.USD","LU2324357040.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","IE00B19Z3581.USD","BK4532","IE00BKVL7J92.USD","BK4566","LU1037948541.HKD","SG9999015945.SGD","BBH","LU0320765992.SGD","LU2112291526.USD","BK4568","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015986.USD","LU1057294990.SGD","LU1585245621.USD","LU2468319806.SGD","LU0058720904.USD","LU0122379950.USD","MEDI","BK4588","GILD","BMED","BK4550","IBB","SG9999015952.SGD","SG9999015978.USD","ASMB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0965509101.SGD","LU0234570918.USD","LU0823416689.USD","LU2468319806.SGD","ASMB","BK4532","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU0859254822.USD","SG9999015952.SGD","LU1934455194.USD","LU0889565916.HKD","LU1037948541.HKD","LU0965508806.USD","TMED","LU1057294990.SGD","LU0965509283.SGD","LU1934455863.HKD","LU2089984988.USD","SG9999015945.SGD","LU1674673428.USD","LU0114720955.EUR","BIB","LU1778281490.HKD","BK4588","IE00B7SZLL34.SGD","BK4550","LU2087621335.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1674673691.USD","LU1061106388.HKD","BK4566","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1934455277.USD","LU0058720904.USD","LU1571399168.USD","LU0861579265.USD","LU1585245621.USD","IE00B3T34201.USD","IBB","IE00BSNM7G36.USD","MEDI","LU2324357040.USD","BK4578","SG9999015978.USD","IBBQ","LU0965509010.AUD","BBH","TBXU","IE00BKVL7J92.USD","LU0882574055.USD","LU1430594728.SGD","BK4139","LU1023059063.AUD","LU1839511570.USD","BMED","LU0109394709.USD","LU0122379950.USD","IE0002270589.USD","SG9999015986.USD","BK4583","GILD","BK4585","LU1066051498.USD","LU2357627491.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1934455863.HKD","BK4566","BK4578","LU1066053197.SGD","LU1585245621.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU0320765992.SGD","BK4550","LU1674673691.USD","LU0861579265.USD","LU0882574055.USD","BK4532","IE00BSNM7G36.USD","LU1037948541.HKD","LU1037948897.HKD","LU1061106388.HKD","LU0114720955.EUR","BK4588","LU1430594728.SGD","TMED","LU2324357040.USD","SG9999015945.SGD","SG9999015986.USD","LU2357627491.SGD","IBBQ","LU0289739699.SGD","BIB","LU0058720904.USD","LU0109394709.USD","MEDI","ASMB","LU0965508806.USD","LU2112291526.USD","SG9999015952.SGD","BK4139","IE0002270589.USD","BK4568","SG9999015978.USD","BK4583","IE00BZ1G4Q59.USD","LU1778281490.HKD","IE00BKVL7J92.USD","LU0965509283.SGD","LU1934455194.USD","LU2087621335.USD","LU2089984988.USD","LU2468319806.SGD","LU1066051498.USD","IBB","LU0823416689.USD","LU1057294990.SGD","LU0965509101.SGD","BBH","LU1674673428.USD","IE00B7SZLL34.SGD","BK4585","LU0859254822.USD","LU1571399168.USD","LU1934455277.USD","LU0889565916.HKD","BMED","LU0234570918.USD","TBXU","GILD","LU0965509010.AUD","LU1839511570.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU2324357040.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","IBBQ","BBH","IE00BSNM7G36.USD","LU1839511570.USD","BK4578","LU1674673691.USD","LU1674673428.USD","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU1430594728.SGD","BIB","LU0122379950.USD","BK4568","LU0861579265.USD","LU1023059063.AUD","LU1037948541.HKD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","IE00B19Z3B42.SGD","LU0859254822.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804697","title":"第4次更新-鑑於市場供應存在擔憂，美國食品藥品監督管理局正與製造商合作，以增加雌激素貼片的供應量","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804697","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804697?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 05:02","pubTimestamp":1788469322,"startTime":"0","endTime":"0","summary":"第4次更新-鉴于市场供应存在担忧，美国食品药品监督管理局正与制造商合作，以增加雌激素贴片的供应量在第10段中补充了拜耳的回应Sriparna Roy路透9月3日-美国卫生监管机构周四表示，在接到患者反映难以及时获得该药物的报告后，该机构正与全部六家制造商合作，以增加用于治疗更年期症状的雌二醇透皮贴片的供应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4S44V1QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4588","AMRX","BK4007","BK4585","VTRS","LU2087621335.USD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178687061","title":"Emergent BioSolutions圓滿完成7500萬美元優先無擔保票據回購","url":"https://stock-news.laohu8.com/highlight/detail?id=1178687061","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178687061?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:49","pubTimestamp":1788436160,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions（EBS）今日宣布，已顺利完成总额达7500万美元的优先无担保票据回购计划。这一财务操作标志着该公司在优化资本结构方面迈出了坚实一步。此次回购涉及的是公司此前发行的优先无担保债券，其回购价格及相关条款均符合市场惯例与公司既定策略。通过此举，Emergent BioSolutions不仅有效降低了未来的利息负担，还进一步增强了资产负债表的灵活性。该公司管理层表示，此次回购体现了其对股东价值创造的持续承诺，未来将继续审慎评估各类资本配置机会，以支持核心业务的长期增长与创新。分析人士认为，此举或将对公司短期财务指标产生积极影响，并提升投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149776488","title":"Emergent BioSolutions獲增購Cyfendus（Av7909）合同修訂——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1149776488","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149776488?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 04:15","pubTimestamp":1788293710,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions（纽交所代码：EBS）于近日向美国证券交易委员会（SEC）提交了一份文件，披露其合同修订情况。\n该修订涉及该公司旗下炭疽疫苗产品Cyfendus（Av7909）的额外采购。根据修订条款，采购方将在原有基础上追加订购更多剂量的Cyfendus。\n这笔增购交易的具体金额和交付时间表尚未在文件中详细披露。公司方面表示，此次合同修改反映了采购方对该疫苗产品的持续需求。\n文件提交后，市场对此消息暂无重大反应。Emergent BioSolutions是一家专注于公共卫生防护领域的生物制药公司，其产品线涵盖炭疽、天花等生物威胁相关疫苗及治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664035851","title":"BUZZ——美國股市動態-Fervo Energy、Myriad Genetics、Emergent BioSolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664035851","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664035851?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:14","pubTimestamp":1788268461,"startTime":"0","endTime":"0","summary":"在股市历史上表现疲软的月份伊始，居高不下的债券收益率和上涨的油价令投资者望而却步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4S44T18L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYGN","EBS","FRVO","BK4583","BK4139","BK4133"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859352","title":"Emergent因獲得2400萬美元炭疽疫苗訂單股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859352","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859352?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 20:17","pubTimestamp":1788265021,"startTime":"0","endTime":"0","summary":"BUZZ-Emergent因获得2400万美元炭疽疫苗订单股价上涨9月1日-** 制药公司Emergent BioSolutions（EBS.N）的股价在盘前交易中上涨3.8%，至6.33美元** 该公司从美国生物医学高级研究与发展局（BARDA）获得了一份价值约2400万美元的订单，将提供其Cyfendus疫苗用于炭疽病防控** “Cyfendus”于2023年获批，是一种两剂疫苗，适用于疑似或","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T14Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}